OVARIAN EPITHELIAL CANCER
Clinical trials for OVARIAN EPITHELIAL CANCER explained in plain language.
Never miss a new study
Get alerted when new OVARIAN EPITHELIAL CANCER trials appear
Sign up with your email to follow new studies for OVARIAN EPITHELIAL CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug combo targets recurrent ovarian cancer in early trial
Disease control Recruiting nowThis study tests a new drug called SKB264 in 20 women with ovarian cancer that has returned after previous treatment. The goal is to see if the drug shrinks tumors and how another drug (clarithromycin) affects its levels in the body. Participants receive the drug intravenously an…
Matched conditions: OVARIAN EPITHELIAL CANCER
Phase: PHASE2 • Sponsor: Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 10:24 UTC
-
New hope for rare cancers: immunotherapy trial targets tumors regardless of origin
Disease control Recruiting nowThis study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control tumors for at least 12 months. About 28 adults who have not responded to standard treatments will take part.
Matched conditions: OVARIAN EPITHELIAL CANCER
Phase: PHASE2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated May 18, 2026 12:13 UTC
-
New dye combo could spare ovarian cancer patients from extensive surgery
Diagnosis Recruiting nowThis study tests whether two special dyes (ICG and a radioactive tracer) can accurately find the first lymph nodes where ovarian cancer might spread. About 62 women with early-stage ovarian cancer will receive both dyes during surgery to see how well they work together. If succes…
Matched conditions: OVARIAN EPITHELIAL CANCER
Phase: NA • Sponsor: Fundacion Clinic per a la Recerca Biomédica • Aim: Diagnosis
Last updated May 20, 2026 11:57 UTC